Meningioma's Genetic Puzzle: How DMD Deletions Impact Progression and Treatment
"Decoding a Novel Link Between a Muscle-Related Gene and Meningioma Severity"
Progressive meningiomas pose a significant challenge in neuro-oncology. These tumors, which have resisted both surgery and radiation, leave patients with limited treatment options and a bleak prognosis. Although meningiomas generally affect more women, aggressive forms disproportionately impact men. Understanding the unique molecular drivers behind these resilient tumors is crucial for developing targeted therapies.
A recent study published in Acta Neuropathologica sheds light on this complex problem. Researchers conducted a comprehensive molecular analysis of 169 meningioma samples from 53 patients with progressive or high-grade tumors. This included examining both initial and recurrent tumor samples to track genetic changes over time.
The findings reveal a surprising connection: deletions in the DMD gene, well-known for causing Duchenne muscular dystrophy, are strongly linked to poorer outcomes in a subset of aggressive meningiomas. This discovery, along with insights into TERT gene alterations, opens new avenues for understanding and potentially treating these challenging tumors.
Current Care and Its Limits
Meningioma care may involve observation, surgery, radiation, or a combination, with decisions shaped by tumor size and location, growth rate, age, overall health, and a patient’s care goals. Observation may be appropriate when immediate treatment is not needed; radiotherapy or radiosurgery may be considered for atypical and anaplastic tumors. Surgery can be complicated when a lesion is near vital structures. The EANO guideline notes that few controlled clinical trials have guided decisions, contributing to variation in management across countries and centers; it also describes molecular genetics and clinical trial results as helping refine care.
DMD Deletions: Unmasking the Culprit in Aggressive Meningiomas
The research team's initial exome sequencing of 24 meningioma samples revealed frequent alterations in genes residing on the X chromosome. Among these, DMD (dystrophin) stood out. Somatic intragenic deletions of DMD were the most common alteration, found in approximately 21% of the initial cohort. Further investigation revealed alterations in other X-linked cancer-related genes such as KDM6A, DDX3X, RBM10, and STAG2, though less frequently.
- DMD encodes dystrophin, a protein crucial for muscle function but also involved in cell structure and signaling.
- DMD deletions were more common in aggressive meningiomas compared to less severe forms.
- The study suggests that loss of dystrophin may disrupt cellular architecture, contributing to tumor progression.
DMD in Higher-Grade Disease
A study of epigenetic subgroups reports recurrent DMD deletions in progressive or higher-grade meningiomas, with deletions primarily affecting exons 1 to 15. A review of meningioma molecular characteristics likewise reports that inactivating DMD mutations are identified in progressive and higher-grade tumors and are associated with poor prognosis. Separately, a study of male meningiomas states that they comprise approximately 30% of all meningiomas and are more frequently high-grade, with poorer clinical outcomes than female meningiomas. In osteosarcoma—not meningioma—MYC gain or amplification was enriched in treatment-resistant clones in 6 of 7 patients with multiple clones, so that finding does not establish a DMD-related meningioma treatment pattern.
Evidence and Longitudinal Limits
In a reported cohort of progressive meningioma patients, DMD inactivation by genomic deletion or loss of protein expression was detected in 17 of 53 patients (32%). The report associates DMD-inactivated tumors with shorter overall survival: 5.1 years (95% CI 1.3–9.0), compared with a median not reached in the wild-type group (95% CI 2.9–not reached). The source also cautions that meningioma genomic alterations evolve over time during treatment and says longitudinal genomic analysis across initial and recurrent disease is likely needed to discover alterations driving recurrence. These findings concern a subset of progressive cases and point to the need for tracking changes over time.
Molecular Testing and Trial Benchmarks
Exome sequencing is justified as a diagnostic test when its results could produce an accurate diagnosis and significantly influence treatment or genetic counseling. For surgery- and radiation-refractory meningioma, a meta-analysis of 47 publications covering different treatment options identified 6-month progression-free survival (PFS) as the endpoint for medical therapy trials. A 2025 review describes the 2021 WHO classification of central nervous system tumors as introducing molecular alterations that affect meningioma grading, alongside a broader review of multidisciplinary management and novel therapies. Together, these sources describe distinct roles for molecular information: informing diagnosis and grading, while clinical trials use defined outcome measures.
A New Path Forward: Targeting DMD and TERT for Improved Meningioma Therapy
The study didn't stop with DMD. Recognizing the established role of TERT alterations in aggressive meningiomas, the researchers also investigated these events. They identified seven patients with TERT promoter mutations and three with TERT rearrangements, including a recurrent and novel RETREG1-TERT rearrangement present in two patients. This dual focus revealed that DMD inactivation and TERT alterations act independently to predict unfavorable outcomes.
Emerging Directions in Care
A 2023 scientometric analysis found that meningioma research over the prior decade focused on management, with surgical treatment and radiation therapy predominating. A 2025 chapter describes an evolving treatment landscape that includes pharmacological approaches using new molecular targets, drug combinations, and gene-editing technology. Penn Medicine’s 2026 discussion emphasizes that emerging treatment options can make decisions complex and that experts from different disciplines need to work together on treatment approaches and patient care. These sources point to continued development of treatment strategies alongside multidisciplinary decision-making.
Multivariate modeling confirmed this independence: DMD inactivation (p=0.033, HR=2.6, 95% CI 1.0-6.6) and TERT alterations (p=0.005, HR=3.8, 95% CI 1.5-9.9) each significantly predicted shorter survival, regardless of the other's presence. This means that future treatment strategies may need to consider both DMD and TERT status to effectively target aggressive meningiomas.
These findings provide a crucial step forward in understanding the genetic underpinnings of aggressive meningiomas. By identifying DMD deletions as a key driver of poor outcomes, the study opens the door for developing novel therapeutic strategies. Furthermore, the independent roles of DMD and TERT suggest that combination therapies targeting both pathways may be necessary to significantly improve patient survival. Future clinical trials should incorporate DMD and TERT stratification to ensure that the most effective treatments are delivered to those who need them most.